BioInvent (Stockholm: BINV.ST) is a biopharmaceutical company developing cancer therapeutics using its wholly-owned antibody drug discovery platform. The Company currently has 4 product candidates in clinical development with novel mechanisms of action. Lead candidate BI-1206 is an antibody targeting CD32b, which is highly expressed in several B-cell malignancies and is associated with resistance to rituximab, the standard of care. A Phase I/IIa study with BI-1206 in relapsed/refractory non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) is ongoing, and initial data are expected in the first half of 2018. Secondary asset TB-403 targets the placental growth factor (PlGF) protein to inhibit neuropilin 1 (Nrp1) signaling as a treatment for medulloblastoma, a rare form of brain cancer that mostly affects children. A Phase I/II study is currently being conducted with TB-403. Additional clinical candidates include THR-317 for diabetic macular edema, and BI-505 for multiple myeloma. BioInvent’s developmental platform is validated by research collaborations with leading pharmaceutical companies that include Pfizer, Bayer, Daiichi-Sankyo, Servier, Mitsubishi Tanabe Pharma, and Xoma.